Abacavir contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 5: | Line 5: | ||
==CONTRAINDICATIONS== | ==CONTRAINDICATIONS== | ||
• ZIAGEN is contraindicated in patients with:previously demonstrated hypersensitivity to abacavir or any other component of the products. | :• ZIAGEN is contraindicated in patients with:previously demonstrated hypersensitivity to abacavir or any other component of the products. | ||
• NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status. | :• NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status. | ||
• Moderate or severe hepatic impairment [see Dosage and Administration] . | :• Moderate or severe hepatic impairment [see Dosage and Administration]. | ||
==References== | ==References== | ||
Revision as of 21:23, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
CONTRAINDICATIONS
- • ZIAGEN is contraindicated in patients with:previously demonstrated hypersensitivity to abacavir or any other component of the products.
- • NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status.
- • Moderate or severe hepatic impairment [see Dosage and Administration].
References
Adapted from the FDA Package Insert.